{"id":89482,"date":"2016-11-23T13:45:05","date_gmt":"2016-11-23T13:45:05","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=89482"},"modified":"2016-11-23T13:45:05","modified_gmt":"2016-11-23T13:45:05","slug":"global-injectable-drug-delivery-market-will-be-worth-usd-7972-billion-by-2022-new-market-report-by-data-bridge-market-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-injectable-drug-delivery-market-will-be-worth-usd-7972-billion-by-2022-new-market-report-by-data-bridge-market-research_89482.html","title":{"rendered":"Global Injectable Drug Delivery Market will be worth USD 797.2 billion by 2022 – New market report by Data Bridge Market Research"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Global Injectable Drug Delivery Market is expected to grow at 12.7% in the forecast period 2016 to 2022”<\/div>\n<\/div>\n<\/div>\n
Global Injectable Drug Delivery Market, By Type (Devices (Conventional Injection Devices, Self Injection Devices), Formulations (Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations), By Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology, Others), By Usage Pattern (Curative Care, Immunizations, Other Usage Patterns), By Mode of Administration, By End User , By Geography \u2013 Trends and Forecast to 2022<\/div>\n

Global Injectable Drug Delivery Market, By Type (Devices (Conventional Injection Devices, Self Injection Devices),  Formulations (Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations), By Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology, Others), By Usage Pattern (Curative Care, Immunizations, Other Usage Patterns), By Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), By End User (Hospitals, Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022<\/strong><\/p>\n

Global Injectable drug delivery market is expected to reach USD 797.2 billion by 2022, from USD 343.2 billion in 2015 growing at a CAGR of 12.7% during the forecast period of 2016 to 2022.<\/p>\n

For Sample Report:  <\/strong>http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/<\/a><\/p>\n

The global injectable drug delivery market is segmented based on product type, application, usage pattern, mode of administration, end-user and geography.<\/p>\n

Based on product type the market is segmented into Devices and Formulations. Devices include conventional injection devices and self-injection devices. The Self Injection devices are further segmented into needle free injector devices, wearable injector devices, pen injector devices and autoinjector devices. Formulations are segmented into conventional drug delivery, novel drug delivery, and long-acting injection formulations. Conventional drug delivery formulations market is further segmented into solutions, reconstituted formulations, suspensions and emulsions. Novel drug delivery formulations market is further segmented based on product type into colloidal dispersions and microparticles. Colloidal dispersions include products such as niosomes, liposomes, polymeric mixed micelles and nanoparticles.<\/p>\n

On the basis of applications the global Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.<\/p>\n

\"\"<\/p>\n

To read more about the scope and findings of this report visit: <\/strong>http:\/\/databridgemarketresearch.com\/injectable-drug-delivery-market-reach-usd-797-2\/<\/a><\/p>\n

On the basis of usage pattern the global injectable drug delivery market is segmented into curative care, immunization and, others.<\/p>\n

Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.<\/p>\n

On the basis of end user the global Injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.<\/p>\n

Based on geography, the market report covers data North America, Europe, Asia-Pacific, South America and rest of the world. The reports of this market further segmented into countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, and South Africa.<\/p>\n

\"\" <\/p>\n

Major players operating in the global injectable drug delivery market are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd.<\/p>\n

To Browse Full Report and Pricing: <\/strong>http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/<\/a><\/p>\n

Table of Content:<\/strong><\/p>\n

1        INTRODUCTION<\/strong><\/p>\n

        1.1.      OVERVIEW OF THE INJECTABLE DRUG DELIVERY MARKET<\/p>\n

        1.2.      MARKET SEGMENTATION & COVERAGE<\/p>\n

                   1.2.1. CURRENCY AND PRICING <\/p>\n

                   1.2.2. LIMITATION<\/p>\n

                   1.2.3. STAKEHOLDERS<\/p>\n

2        RESEARCH METHODOLOGY<\/strong><\/p>\n

        2.1.      KEY TAKEAWAYS<\/p>\n

        2.2.      ARRIVING AT THE INJECTABLE DRUG DELIVERY MARKET SIZE<\/p>\n

                   2.2.1. MARKET CRACKDOWN APPROACH <\/p>\n

                   2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS<\/p>\n

                   2.2.3. DATA TRIANGULATION<\/p>\n

                   2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES<\/p>\n

                   2.2.5.  KEY DATA POINTS FROM SECONDARY SOURCES<\/p>\n

                   2.2.6.  PORTER’S FIVE FORCES MATRIX<\/p>\n

        2.3.      GLOBAL INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT<\/p>\n

        2.4.      ASSUMPTIONS<\/p>\n

3        MARKET LANDSCAPE SUMMARY<\/strong><\/p>\n

4        PREMIUM INSIGHTS<\/strong><\/p>\n

        4.1.      OVERVIEW<\/p>\n

        4.2.      INJECTABLE DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS<\/p>\n

        4.3.      MARKET OVERVIEW<\/p>\n

                   4.3.1. DRIVERS<\/p>\n

                            4.3.1.1.   RISING PREVALENCE OF CHRONIC DISEASES<\/p>\n

                            4.3.1.2.   INCRESING DEMAND OF SELF INJECTION DEVICES<\/p>\n

                            4.3.1.3.   GROWTH OF BILOGICS AND BIOSIMILARS MARKET<\/p>\n

                            4.3.1.4.   TECHNOLOGICAL ADVANCEMENTS IN DRUG DELIVERY MARKET<\/p>\n

                   4.3.2. RESTRAINTS<\/p>\n

                   4.3.3. OPPURTUNITIES<\/p>\n

                            4.3.3.1.   INCRESING DEMAND FOR GENERIC INJECTABLES<\/p>\n

                   4.3.4. THREATS<\/p>\n

                            4.3.4.1.   PRODUCT RECALLS<\/p>\n

                            4.3.4.2.   REGULATORY HURDLES<\/p>\n

                            4.3.4.3.   STABILITY OF PRODUCTS<\/p>\n

                            4.3.4.4.   STERILITY OF INJECTIONS<\/p>\n

                            4.3.4.5.   GROWING DEMAND OF OTHER DRUG DELIVERY TECHNOLOGIES<\/p>\n

        4.4.      KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES<\/p>\n

5        INJECTABLE DRUG DELIVERY MARKET, BY TYPE<\/strong><\/p>\n

        5.1.      OVERVIEW<\/p>\n

        5.2.      INJECTABLE DRUG DELIVERY DEVICES<\/p>\n

        5.3.      INJECTABLE DRUG DELIVERY FORMULATIONS<\/p>\n

6        INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE<\/strong><\/p>\n

        6.1.      OVERVIEW<\/p>\n

        6.2.      CONVENTIONAL INJECTION DEVICES<\/p>\n

                   6.2.1. BY MATERIAL<\/p>\n

                            6.2.1.1.   GLASS<\/p>\n

                            6.2.1.2.   PLASTIC<\/p>\n

                            6.2.2. BY PRODUCT<\/p>\n

                            6.2.2.1.   EMPTY SYRINGES<\/p>\n

                            6.2.2.2.   PREFILLED SYRINGES<\/p>\n

                   6.2.3. BY USABLITY<\/p>\n

                            6.2.3.1.   REUSABLE SYRINGES<\/p>\n

                            6.2.3.2.   DISPOSABLE SYRINGES<\/p>\n

        6.3.      SELF INJECTION DEVICES<\/p>\n

                   6.3.1. NEEDLE FREE INJECTORS<\/p>\n

                            6.3.1.1.   BY PRODUCT<\/p>\n

                                         6.3.1.1.1.   EMPTY NEEDLE FREE INJECTORS<\/p>\n

                                         6.3.1.1.2.   PREFILLED NEEDLE FREE INJECTORS<\/p>\n

                            6.3.1.2.   BY TECHNOLOGY<\/p>\n

                                         6.3.1.2.1.   JET BASED NEEDLE FREE INJECTORS<\/p>\n

                                         6.3.1.2.2.   SPRING BASED NEEDLE FREE INJECTORS<\/p>\n

                                         6.3.1.2.3.   LASER POWERED NEEDLE FREE INJECTORS<\/p>\n

                                         6.3.1.2.4.   VIBRATION BASED NEEDLE FREE INJECTORS<\/p>\n

                            6.3.1.3.   BY USABILITY<\/p>\n

                                         6.3.1.3.1.   REUSABLE NEEDLE FREE INJECTORS<\/p>\n

                                         6.3.1.3.2.   DISPOSABLE NEEDLE FREE INJECTORS<\/p>\n

                   6.3.2. AUTOINJECTORS<\/p>\n

                            6.3.2.1.   BY PRODUCT<\/p>\n

                                         6.3.2.1.1.   EMPTY AUTOINJECTORS<\/p>\n

                                         6.3.2.1.2.   PREFILLED AUTOINJECTORS<\/p>\n

                            6.3.2.2.   BY TECHNOLOGY<\/p>\n

                                         6.3.2.2.1.   AUTOMATED AUTOINJECTORS<\/p>\n

                                         6.3.2.2.2.   MANUAL AUTOINJECTORS<\/p>\n

                            6.3.2.3.   BY DESIGN<\/p>\n

                                         6.3.2.3.1.   STANDARDIZED AUTOINJECTORS<\/p>\n

                                         6.3.2.3.2.   CUSTOMIZED AUTOINJECTORS<\/p>\n

                            6.3.2.4.   BY USABILITY<\/p>\n

                                         6.3.2.4.1.   REUSABLE AUTOINJECTORS<\/p>\n

                                         6.3.2.4.2.   DISPOSABLE AUTOINJECTORS<\/p>\n

                   6.3.3. PEN INJECTORS<\/p>\n

                            6.3.3.1.   BY PRODUCT<\/p>\n

                                         6.3.3.1.1.   SINGLE CHAMBERED PEN INJECTORS<\/p>\n

                                         6.3.3.1.2.   DUAL CHAMBERED PEN INJECTORS<\/p>\n

                            6.3.3.2.   BY DESIGN<\/p>\n

                                         6.3.3.2.1.   STANDARDIZED PEN INJECTORS<\/p>\n

                                         6.3.3.2.2.   CUSTOMIZED PEN INJECTORS<\/p>\n

                            6.3.3.3.   BY USABILITY<\/p>\n

                                         6.3.2.3.1.   REUSABLE PEN INJECTORS<\/p>\n

                                         6.3.2.3.2.   DISPOSABLE PEN INJECTORS<\/p>\n

                   6.3.4. WEARABLE INJECTORS<\/p>\n

                   6.3.5. OTHER INJECTABLE DEVICES<\/p>\n

7        INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY PRODUCT TYPE<\/strong><\/p>\n

        7.1.      OVERVIEW<\/p>\n

        7.2.      CONVENTIONAL DRUG DELIVERY FORMULATIONS<\/p>\n

                   7.2.1. SOLUTIONS<\/p>\n

                   7.2.2. RECONSTITUTED\/LYOPHILIZED FORMULATIONS<\/p>\n

                   7.2.3. SUSPENSIONS<\/p>\n

                   7.2.4. EMULSIONS<\/p>\n

        7.3.      NOVEL DRUG DELIVERY FORMULATIONS<\/p>\n

                   7.3.1. COLLOIDAL DISPERSIONS<\/p>\n

                            7.3.1.1.   LIPOSOMES<\/p>\n

                            7.3.1.2.   NIOSOMES<\/p>\n

                            7.3.1.3.   POLYMERIC MIXED MICELLES<\/p>\n

                            7.3.1.4.   NANOPARICLES<\/p>\n

                                         7.3.1.4.1.   NANOSUSPENSIONS<\/p>\n

                                         7.3.1.4.2.   NANOEMULSIONS\/MICROEMULSIONS<\/p>\n

                                         7.3.1.4.3.   SOLID LIPID NANOPARTICLES<\/p>\n

                   7.3.2. MICROPARTICLES<\/p>\n

                            7.3.2.1.   MICROSPHERES<\/p>\n

                            7.3.2.2.   MICROCAPSULES<\/p>\n

                   7.3.3. LONG ACTING INJECTION FORMULATIONS<\/p>\n

8        INJECTABLE DRUG DELIVERY MARKET, BY APPLICATIONS<\/strong><\/p>\n

        8.1.      OVERVIEW<\/p>\n

        8.2.      AUTOIMMUNE DISEASES<\/p>\n

                   8.2.1. RHEUMATOID ARTHRITIS<\/p>\n

                   8.2.2. MULTIPLE SCLEROSIS<\/p>\n

                   8.2.3. CHRON’S DISEASE<\/p>\n

                   8.2.4. PSORIASIS<\/p>\n

                   8.2.5. OTHER AUTOIMMUNE DISEASES<\/p>\n

        8.3.      HORMONAL DISORDERS<\/p>\n

                   8.3.1. DIABETES<\/p>\n

                   8.3.2. ANEMIA<\/p>\n

                   8.3.3. REPRODUCTIVE HEALTH DISEASE<\/p>\n

                   8.3.4. ANTITHROMBOTIC\/THROMBOLYTIC THERAPY<\/p>\n

                   8.3.5. OSTEOPOROSIS<\/p>\n

                   8.3.6. GROWTH HORMONE DEFICIENCY (GHD)<\/p>\n

        8.4.      ORPHAN DISEASES<\/p>\n

        8.5.      ONCOLOGY<\/p>\n

        8.6.      OTHERS<\/p>\n

                   8.6.1. PAIN MANAGEMENT<\/p>\n

                   8.6.2. ALERGY TREATMENT<\/p>\n

                   8.6.3. AESTHETIC TREATMENTS<\/p>\n

                   8.6.4. HEPATITIS C<\/p>\n

                   8.6.5. HEMOPHILIA<\/p>\n

9        INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN<\/strong><\/p>\n

        9.1.      OVERVIEW<\/p>\n

        9.2.      CURATIVE CARE<\/p>\n

        9.3.      IMMUNIZATIONS<\/p>\n

        9.4.      OTHER USAGE PATTERNS (BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES)<\/p>\n

10      INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION<\/strong><\/p>\n

        10.1.   OVERVIEW<\/p>\n

        10.2.   SKIN<\/p>\n

        10.3.   CIRCULATORY\/MUSKOSKELETAL<\/p>\n

        10.4.   ORGANS<\/p>\n

        10.5.   CENTRAL NERVOUS SYSTEM<\/p>\n

11      INJECTABLE DRUG DELIVERY MARKET, BY END USER<\/strong><\/p>\n

        11.1.   OVERVIEW<\/p>\n

        11.2.   HOSPITALS AND CLINICS<\/p>\n

        11.3.   HOME HEALTHCARE SETTINGS<\/p>\n

        11.4.   RESEARCH LABORATORIES<\/p>\n

        11.5.   PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES<\/p>\n

        11.6.   OTHER END USERS<\/p>\n

12      INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY<\/strong><\/p>\n

        12.1.   COUNTRYWISE SLEEP APNEA DEVICES MARKET, (ALL     SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN                   THIS CHAPTER BY COUNTRY)<\/p>\n

                  12.1.1.      NORTH AMERICA<\/p>\n

                                 12.1.1.1.      U.S.<\/p>\n

                                 12.1.1.2.      CANADA<\/p>\n

                                 12.1.1.3.      MEXICO<\/p>\n

                  12.1.2.      EUROPE<\/p>\n

                                 12.1.2.1.      GERMANY<\/p>\n

                                 12.1.2.2.      FRANCE<\/p>\n

                                 12.1.2.3.      U.K.<\/p>\n

                                 12.1.2.4.      ITALY<\/p>\n

                                 12.1.2.5.      SPAIN<\/p>\n

                                 12.1.2.6.      RUSSIA<\/p>\n

                                 12.1.2.7.      TURKEY<\/p>\n

                                 12.1.2.8.      BELGIUM<\/p>\n

                                 12.1.2.9.      NETHERLANDS<\/p>\n

                                 12.1.2.7.      SWITZERLAND<\/p>\n

                                 12.1.2.8.    REST OF EUROPE<\/p>\n

                  12.1.3.      ASIA-PACIFIC (APAC)<\/p>\n

                                 12.1.3.1.      JAPAN<\/p>\n

                                 12.1.3.2.      CHINA<\/p>\n

                                 12.1.3.3.      SOUTH KOREA<\/p>\n

                                 12.1.3.4.      INDIA<\/p>\n

                                 12.1.3.5.      AUSTRALIA<\/p>\n

                                 12.1.3.6.      SINGAPORE<\/p>\n

                                 12.1.3.7.      THAILAND<\/p>\n

                                 12.1.3.8.      MALAYSIA<\/p>\n

                                 12.1.3.9.      INDONESIA<\/p>\n

                                 12.1.3.10.      PHILIPPINES<\/p>\n

                                 12.1.3.11.      REST OF APAC<\/p>\n

                  12.1.4.    LATIN AMERICA<\/p>\n

                               12.1.4.1.     BRAZIL<\/p>\n

                               12.1.4.2.     REST OF LATIN AMERICA<\/p>\n

                  12.1.5.    MIDDLE EAST AND AFRICA<\/p>\n

                               12.1.5.1.     SOUTH AFRICA<\/p>\n

                               12.1.5.2.     REST OF MIDDLE EAST AND AFRICA<\/p>\n

        12.2.   KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES<\/p>\n

13      INJECTABLE DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE<\/strong><\/p>\n

        13.1.   GLOBAL INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.2.   U.S. INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.3.   EUROPE INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.4.   APAC INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.5.   SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.6.   MIDDLE EAST AND AFRICA  INJECTABLE DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS<\/p>\n

        13.7.   MERGERS & ACQUISITIONS<\/p>\n

        13.8.   NEW PRODUCT DEVELOPMENT & APPROVALS<\/p>\n

        13.9.   EXPANSIONS                            <\/p>\n

        13.10. REGULATORY CHANGES<\/p>\n

        13.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS<\/p>\n

14      INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES <\/strong><\/p>\n

        14.1    BAXTER INTERNATIONAL, INC.<\/p>\n

                  14.1.1   OVERVIEW<\/p>\n

                  14.1.2   SWOT ANALYSIS<\/p>\n

                  14.1.3   PRODUCT PORTFOLIO<\/p>\n

                  14.1.4   REVENUE ANALYSIS<\/p>\n

                  14.1.5   ANALYSTS VIEW<\/p>\n

        14.2    BECTON, DICKINSON AND COMPANY<\/p>\n

                 14.2.1   OVERVIEW<\/p>\n

                 14.2.2   SWOT ANALYSIS<\/p>\n

                 14.2.3   PRODUCT PORTFOLIO<\/p>\n

                 14.2.4   REVENUE ANALYSIS<\/p>\n

                 14.2.5   ANALYSTS VIEW<\/p>\n

        14.3    GERRESHEIMER, AG<\/p>\n

                  14.3.1   OVERVIEW<\/p>\n

                  14.3.2   SWOT ANALYSIS<\/p>\n

                  14.3.3   PRODUCT PORTFOLIO<\/p>\n

                  14.3.4   REVENUE ANALYSIS<\/p>\n

                  14.3.5   ANALYST VIEW<\/p>\n

        14.4    PFIZER, INC.<\/p>\n

                  14.4.1   OVERVIEW<\/p>\n

                  14.4.2   SWOT ANALYSIS<\/p>\n

                  14.4.3   PRODUCT PORTFOLIO<\/p>\n

                  14.4.4   REVENUE ANALYSIS<\/p>\n

                  14.4.5   ANALYSTS VIEW<\/p>\n

        14.5    SCHOTT AG<\/p>\n

                  14.5.1   OVERVIEW<\/p>\n

                  14.5.2   SWOT ANALYSIS<\/p>\n

                  14.5.3   PRODUCT PORTFOLIO<\/p>\n

                  14.5.4   REVENUE ANALYSIS<\/p>\n

                  14.5.5   ANALYSTS VIEW<\/p>\n

        14.6    ALKERMES PLC<\/p>\n

                  14.6.1   OVERVIEW<\/p>\n

                  14.6.2   SWOT ANALYSIS<\/p>\n

                  14.6.3   PRODUCT PORTFOLIO<\/p>\n

                  14.6.4   REVENUE ANALYSIS<\/p>\n

                  14.6.5   ANALYSTS VIEW<\/p>\n

        14.7    ELI LILLY AND COMPANY<\/p>\n

                  14.7.1   OVERVIEW<\/p>\n

                  14.7.2   SWOT ANALYSIS<\/p>\n

                  14.7.3   PRODUCT PORTFOLIO<\/p>\n

                  14.7.4   REVENUE ANALYSIS<\/p>\n

                  14.7.5   ANALYSTS VIEW<\/p>\n

        14.8    SANDOZ<\/p>\n

                 14.8.1   OVERVIEW<\/p>\n

                 14.8.2   SWOT ANALYSIS<\/p>\n

                 14.8.3   PRODUCT PORTFOLIO<\/p>\n

                 14.8.4   REVENUE ANALYSIS<\/p>\n

                 14.8.5   ANALYSTS VIEW<\/p>\n

        14.9    TERUMO CORPORATION<\/p>\n

                 14.9.1   OVERVIEW<\/p>\n

                 14.9.2   SWOT ANALYSIS<\/p>\n

                 14.9.3   PRODUCT PORTFOLIO<\/p>\n

                 14.9.4   REVENUE ANALYSIS<\/p>\n

                 14.9.5   ANALYSTS VIEW<\/p>\n

        14.10  TEVA PHARMACEUTICAL INDUSTRIES LTD.<\/p>\n

                 14.10.1   OVERVIEW<\/p>\n

                 14.10.2   SWOT ANALYSIS<\/p>\n

                 14.10.3   PRODUCT PORTFOLIO<\/p>\n

                 14.10.4   REVENUE ANALYSIS<\/p>\n

                 14.10.5   ANALYSTS VIEW<\/p>\n

15      APPENDIX <\/strong><\/p>\n

        15.1    RELATED REPORTS<\/p>\n

        15.2    CUSTOMIZABLE OPTIONS<\/p>\n

        15.3    SOURCE SHEET<\/p>\n

        15.4    BIBLIOGRAPHY<\/p>\n

16      ABOUT DATA BRIDGE MARKET RESEARCH <\/strong><\/p>\n

About Data Bridge Market Research:<\/strong><\/p>\n

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are one of the largest market research firms in terms of number of reports produced, also we are proud to be the makers of the lengthiest reports in the industry owing to our in depth segmentation and large geographical coverage. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.<\/strong><\/p>\n

Reports:<\/strong><\/p>\n

Global Drug Delivery Devices Market – Trends and Forecast to 2022<\/a><\/p>\n

By Product Type (Oral (Solid, Liquid,Semi-Solid), Injectable (Devices (Conventional, Self-Injectable), Formulations), Topical (Transdermal Devices (Patches, Gels), Formulations), Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare, Others), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tenders, Online Pharmacy), By Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa, Rest of the World) – Trends and Forecast to 2022<\/strong><\/p>\n

Global Cord Stem Cell Banking Market – Trends and Forecast to 2022<\/a><\/p>\n

By Storage Type (Private Banking, Public Banking), By Product Type (Cord Blood, Cord Blood & Cord Tissue), By Service Type (Collection & Transportation, Processing, Analysis, Storage), By Source (Umbilical Cord Blood, Bone Marrow, Peripheral Blood Stem, Menstrual Blood), By Indication (Cerebral Palsy, Thalassemia, Leukemia, Diabetes, Autism), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Data Bridge Market Research Private Limited
Contact Person:<\/strong> Shubham Dwivedi
Email:<\/strong> Sales@databridgemarketresearch.com
Phone:<\/strong> +1-888-387-2818
Address:<\/strong>Mega Center, Magarpatta City
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> http:\/\/databridgemarketresearch.com\/reports\/global-injectable-drug-delivery-market\/<\/a><\/p>\n

<\/object><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Global Injectable Drug Delivery Market is expected to grow at 12.7% in the forecast period 2016 to 2022” Global Injectable Drug Delivery Market, By Type (Devices (Conventional Injection Devices, Self Injection Devices), Formulations (Conventional Drug Delivery, Noble Drug Delivery, Long … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-89482","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/89482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=89482"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/89482\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=89482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=89482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=89482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}